1. Home
  2. ADNT vs CRVS Comparison

ADNT vs CRVS Comparison

Compare ADNT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adient plc

ADNT

Adient plc

HOLD

Current Price

$19.33

Market Cap

1.5B

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.96

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADNT
CRVS
Founded
2016
2014
Country
Ireland
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2016
2016

Fundamental Metrics

Financial Performance
Metric
ADNT
CRVS
Price
$19.33
$12.96
Analyst Decision
Buy
Strong Buy
Analyst Count
11
6
Target Price
$25.41
$30.17
AVG Volume (30 Days)
796.9K
661.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
0.38
N/A
Revenue
$17,439,000,000.00
N/A
Revenue This Year
$2.71
N/A
Revenue Next Year
$2.36
N/A
P/E Ratio
$48.21
N/A
Revenue Growth
7.56
N/A
52 Week Low
$17.68
$5.64
52 Week High
$27.32
$26.95

Technical Indicators

Market Signals
Indicator
ADNT
CRVS
Relative Strength Index (RSI) 44.82 36.72
Support Level $18.11 $12.76
Resistance Level $22.52 $14.00
Average True Range (ATR) 0.79 0.56
MACD -0.02 -0.16
Stochastic Oscillator 31.33 10.78

Price Performance

Historical Comparison
ADNT
CRVS

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: